Graham D T, Pomeroy A R, Smythe D B
Med J Aust. 1979 Jan 27;1(2):45-6. doi: 10.5694/j.1326-5377.1979.tb111969.x.
In-vitro study which duplicated the conditions to which the orally administered pancreatin is exposed in the human stomach showed that the oral administration of pancreatin in uncoated powder form could result in a substantial loss of enzymic activity. Therefore, it may not be an efficacious replacement therapy in pancreatic disorders where pancreatin secretion is reduced.
一项体外研究模拟了口服胰酶在人体胃内所面临的条件，结果显示，口服未包衣粉末形式的胰酶会导致酶活性大幅丧失。因此，在胰酶分泌减少的胰腺疾病中，它可能不是一种有效的替代疗法。
